CTNNB1 mutation analysis (or perhaps beta‐catenin immunohistochemistry as a surrogate), L1 cell adhesion molecule (L1CAM), and p53 may be of value in low‐grade endometrioid carcinomas in identifying those cases likely to have a worse outcome.15 Here, CTNNB1 is linked to endometrioid adenocarcinoma.